Opportunity Information: Apply for PAR 08 206
Apply for PAR 08 206
- The National Institutes of Health in the health income security and social services sector is offering a public funding opportunity titled "Investigations on Primary Immunodeficiency Diseases (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders 93.855 Allergy, Immunology and Transplantation Research 93.865 Child Health and Human Development Extramural Research.
- This funding opportunity was created on May 25, 2011 and posted on Jul 18, 2008.
- Applicants must submit their applications by Jan 7, 2012. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Native American tribal governments (Federally recognized) State governments Native American tribal organizations (other than Federally recognized tribal governments) Small businesses Special district governments City or township governments Public housing authorities/Indian housing authorities For profit organizations other than small businesses Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) Independent school districts Private institutions of higher education County governments Public and State controlled institutions of higher education.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Investigations on Primary Immunodeficiency Diseases (R01) opportunity (Funding Opportunity Number PAR-08-206) is an NIH discretionary research grant designed to push forward innovative work on primary immunodeficiency diseases (PIDs). It is co-sponsored by multiple NIH institutes, including the National Institute of Allergy and Infectious Diseases (NIAID), the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the National Institute of Neurological Disorders and Stroke (NINDS), and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The overall emphasis is on generating deeper biological understanding of these disorders and translating that understanding into better ways to detect, define, and ultimately treat them, while staying within the scope of research that does not involve clinical trials.
A central feature of the announcement is its focus on strong experimental investigation using either ex vivo studies with human specimens or studies using animal models. On the human side, this points to research that leverages patient-derived samples such as blood, immune cells, tissues, or other clinically obtained specimens to characterize immune defects, clarify functional consequences of suspected genetic variants, or map disease mechanisms in relevant cell types. On the animal-model side, the FOA explicitly welcomes work using existing models as well as development of new models, which can be important for testing mechanistic hypotheses, understanding disease progression, and evaluating therapeutic concepts in vivo before moving toward later-stage human testing.
In addition to lab-based and model-based research, the FOA also supports novel clinical strategies that improve the detection and characterization of PIDs, with the important boundary that clinical trials are not included. In practice, this means applicants can propose clinically oriented research such as improved diagnostic approaches, new screening or identification strategies, genotype-phenotype correlation studies, biomarker development, and efforts to define the molecular basis of disease. Projects can also aim to develop innovative therapies at a preclinical or translational stage, such as proof-of-concept therapeutic strategies, mechanism-driven intervention development, or other research intended to build the scientific foundation for future clinical testing, provided the proposed work is not itself a clinical trial.
The mechanism is the NIH R01, which typically supports hypothesis-driven, investigator-initiated research programs of substantial scope. The announcement also explicitly encourages applications from investigators who have not previously received independent NIH funding in this field, signaling an intent to attract new groups and fresh perspectives into PID research, whether those investigators are coming from adjacent immunology areas, genetics, neurology, infectious disease, pediatrics, systems biology, or other relevant disciplines.
Eligibility is broad and includes a wide range of organization types. Eligible applicants listed include public and state-controlled institutions of higher education and private institutions of higher education; nonprofits with or without 501(c)(3) status; for-profit organizations (including those other than small businesses and also small businesses); state, county, city or township governments; special district governments; independent school districts; public housing authorities/Indian housing authorities; and multiple categories of tribal governments and tribal organizations. The eligibility description also extends to groups such as Alaska Native and Native Hawaiian Serving Institutions, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, regional organizations, U.S. territories or possessions, and certain non-U.S. (foreign) entities, reflecting NIH’s generally inclusive approach to soliciting strong biomedical research proposals. There is no cost sharing or matching requirement attached to this opportunity.
From an administrative standpoint, the FOA falls under health-related funding activity categories and is associated with multiple CFDA numbers tied to NIH extramural research areas, including allergy/immunology and transplantation research, child health and development, and neurosciences/neurological disorders, underscoring that PIDs often have multi-system consequences and can intersect with infectious disease susceptibility, developmental issues, metabolic complications, and neurologic manifestations. Key dates provided for this announcement include a posted date of July 18, 2008, an original closing date of September 7, 2011, and a current closing date of January 7, 2012, with an archive date of February 7, 2012, indicating that this is a historical funding opportunity rather than an open, active solicitation.
The official announcement and full details were made available through the NIH Grants Guide (link provided in the source text). For access or technical issues, the contact listed is the NIH Office of Extramural Research (OER) webmaster.
Frequently Asked Questions (FAQs)
What is the purpose of the Investigations on Primary Immunodeficiency Diseases (R01) opportunity?
This NIH R01 funding opportunity (PAR-08-206) is intended to advance innovative research on primary immunodeficiency diseases (PIDs). The emphasis is on generating deeper biological understanding of these disorders and translating that knowledge into better ways to detect, define, and ultimately treat PIDs, while staying within the scope of research that does not involve clinical trials.
What is the Funding Opportunity Number (FOA number)?
The Funding Opportunity Number is PAR-08-206.
What grant mechanism is used for this opportunity?
This opportunity uses the NIH R01 mechanism, which generally supports hypothesis-driven, investigator-initiated research programs of substantial scope.
Which NIH institutes co-sponsor this FOA?
The FOA is co-sponsored by multiple NIH institutes, including the National Institute of Allergy and Infectious Diseases (NIAID), the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the National Institute of Neurological Disorders and Stroke (NINDS), and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
What types of research are emphasized in this FOA?
A central feature is strong experimental investigation using either ex vivo studies with human specimens or studies using animal models. The FOA also supports clinically oriented strategies that improve detection and characterization of PIDs, as long as the work does not constitute a clinical trial.
Does this FOA allow clinical trials?
No. The overall scope explicitly excludes clinical trials. Projects may be clinically oriented (such as diagnostics, screening, and characterization), but the proposed work must not be a clinical trial.
What does "ex vivo studies with human specimens" mean in the context of this FOA?
It refers to research using patient-derived samples (such as blood, immune cells, tissues, or other clinically obtained specimens) to characterize immune defects, clarify functional consequences of suspected genetic variants, or map disease mechanisms in relevant cell types.
What kinds of animal model work does the FOA encourage?
The FOA welcomes studies using existing animal models as well as the development of new models. These approaches can be used to test mechanistic hypotheses, understand disease progression, and evaluate therapeutic concepts in vivo prior to later-stage human testing.
Can applicants propose work on improved diagnosis or screening for PIDs?
Yes. The FOA supports novel clinical strategies that improve detection and characterization of PIDs, including improved diagnostic approaches and new screening or identification strategies, provided the work does not involve clinical trials.
Are genotype-phenotype correlation studies and biomarker development within scope?
Yes. Examples of clinically oriented research within scope include genotype-phenotype correlation studies, biomarker development, and efforts to define the molecular basis of disease, as long as the project is not a clinical trial.
Can projects focus on therapies?
Yes, at a preclinical or translational stage. The FOA supports development of innovative therapies such as proof-of-concept therapeutic strategies or mechanism-driven intervention development intended to build the scientific foundation for future clinical testing, provided the proposed work itself is not a clinical trial.
Are new investigators encouraged to apply?
Yes. The announcement explicitly encourages applications from investigators who have not previously received independent NIH funding in this field, reflecting an intent to attract new groups and fresh perspectives into PID research.
What disciplines or backgrounds might be relevant for applicants?
The FOA encourages fresh perspectives, including investigators coming from adjacent immunology areas, genetics, neurology, infectious disease, pediatrics, systems biology, and other relevant disciplines connected to PID research.
Who is eligible to apply?
Eligibility is broad and includes many organization types, such as public and state-controlled institutions of higher education; private institutions of higher education; nonprofits (with or without 501(c)(3) status); for-profit organizations (including small businesses and other than small businesses); state, county, city or township governments; special district governments; independent school districts; public housing authorities/Indian housing authorities; and multiple categories of tribal governments and tribal organizations.
Are specific institution types (e.g., HSIs, HBCUs, TCCUs) mentioned as eligible?
Yes. The eligibility description extends to organization types including Alaska Native and Native Hawaiian Serving Institutions, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), and Tribally Controlled Colleges and Universities (TCCUs), among others.
Are faith-based or community-based organizations eligible?
Yes. Faith-based or community-based organizations are included in the eligibility description.
Are U.S. territories or possessions included in eligibility?
Yes. The eligibility description includes U.S. territories or possessions.
Are non-U.S. (foreign) entities eligible?
Yes. The eligibility description includes certain non-U.S. (foreign) entities.
Is there a cost sharing or matching requirement?
No. The FOA states that there is no cost sharing or matching requirement.
What funding activity category does this FOA fall under?
It falls under health-related funding activity categories and is associated with NIH extramural research areas spanning allergy/immunology and transplantation research, child health and development, and neurosciences/neurological disorders.
Why are multiple NIH research areas associated with this FOA?
The FOA reflects that primary immunodeficiency diseases can have multi-system consequences and may intersect with infectious disease susceptibility, developmental issues, metabolic complications, and neurologic manifestations.
Is this funding opportunity currently open?
No. The dates indicate it is a historical funding opportunity rather than an open, active solicitation.
What are the key dates listed for this FOA?
Key dates provided include a posted date of July 18, 2008; an original closing date of September 7, 2011; a current closing date of January 7, 2012; and an archive date of February 7, 2012.
Where were the official announcement and full details published?
The official announcement and full details were made available through the NIH Grants Guide (with a link provided in the source information).
Who is listed as the contact for access or technical issues?
The contact listed for access or technical issues is the NIH Office of Extramural Research (OER) webmaster.
Browse more opportunities from the same category: Health Income Security and Social Services
Next opportunity: Pilot studies in Pancreatic Cancer (R21)
Previous opportunity: NIDCD Phase III Definitive Clinical Trials in Communication Disorders (R01)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 08 206
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 08 206) also looked into and applied for these:
| Funding Opportunity |
|---|
| Biosocial Approaches to Infertility Research (R21) Apply for PA 09 032 Funding Number: PA 09 032 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $200,000 |
| Womens Reproductive Health Research (WRHR) Career Development Program (K12) Apply for RFA HD 08 014 Funding Number: RFA HD 08 014 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $440,000 |
| Population Research Infrastructure Program Short term Support for Rising Programs (R24) Apply for PAR 07 401 Funding Number: PAR 07 401 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $150,000 |
| Collaborative Pediatric Critical Care Research Network (U10) Apply for RFA HD 08 025 Funding Number: RFA HD 08 025 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Postdoctoral Research Training for Obstetricians and Gynecologists (T32) Apply for PAR 09 049 Funding Number: PAR 09 049 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Obstetric Pharmacology Research Units (U10) Apply for RFA HD 09 002 Funding Number: RFA HD 09 002 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $650,000 |
| Advanced Neural Prosthetics Research and Development (U01) Apply for PA 09 063 Funding Number: PA 09 063 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Enhancing Developmental Biology Research at Undergraduate Institutions Academic Research Enhancement Award (R15) Apply for PAR 09 084 Funding Number: PAR 09 084 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $150,000 |
| Advanced Tools and Technologies for Deep Brain Stimulation in Movement Disorders SBIR (R43/R44) Apply for PA 07 396 Funding Number: PA 07 396 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Academic Community Partnership Conference Series (U13) Apply for PAR 09 092 Funding Number: PAR 09 092 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $30,000 |
| Childhood Obesity Prevention and Treatment Research Consortium (U01) Apply for RFA HL 10 004 Funding Number: RFA HL 10 004 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Childhood Obesity Prevention and Treatment Research Coordinating Unit (U01) Apply for RFA HL 10 005 Funding Number: RFA HL 10 005 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Outcomes Research in Orthotics and Prosthetics (R01) Apply for RFA HD 09 007 Funding Number: RFA HD 09 007 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $350,000 |
| Translational Research in Pediatric and Obstetric Pharmacology (R03) Apply for PAR 09 154 Funding Number: PAR 09 154 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Translational Research in Pediatric and Obstetric Pharmacology (R01) Apply for PAR 09 155 Funding Number: PAR 09 155 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Translational Research in Pediatric and Obstetric Pharmacology (R21) Apply for PAR 09 156 Funding Number: PAR 09 156 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $275,000 |
| Womens Reproductive Health Research (WRHR) Career Development Program (K12) Apply for RFA HD 09 026 Funding Number: RFA HD 09 026 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $440,000 |
| Considerations For The Safe and Effective Use of Iron Interventions In Context of Malaria and Its Co morbidities (U01) Apply for RFA HD 09 029 Funding Number: RFA HD 09 029 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Factors Affecting Cognitive Function in Adults with Down Syndrome (R01) Apply for RFA HD 09 028 Funding Number: RFA HD 09 028 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $500,000 |
| Noninvasive Assays of Human Oocytes and Preimplantation Embryos (STTR R41) Apply for RFA HD 09 024 Funding Number: RFA HD 09 024 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $100,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 08 206", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.